Academic Journal
Brazilian cohort results of the PRECONNECT study: safety and efficacy of trifluridine/tipiracil in metastatic colorectal cancer
| العنوان: | Brazilian cohort results of the PRECONNECT study: safety and efficacy of trifluridine/tipiracil in metastatic colorectal cancer |
|---|---|
| المؤلفون: | Celso Abdon Lopes de Mello, Felipe Melo Cruz, Fernando Meton de Alencar Camara Vieira, Alan Arrieira Azambuja, Luiz A Senna Leite, Luciana Mardegan, Andreia Gil, Loïck Vidot, Anelisa Coutinho |
| المصدر: | Brazilian Journal of Oncology, Vol 18, Iss 00 (2022) |
| بيانات النشر: | Sociedade Brasileira de Oncologia Clínica, Sociedade Brasileira de Cirurgia Clínica and Sociedade Brasileira de Radioterapia, 2022. |
| سنة النشر: | 2022 |
| المجموعة: | LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens LCC:Medicine |
| مصطلحات موضوعية: | trifluridine/tipiracil, colorectal cancer, metastatic colorectal cancer, refractory disease, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282, Medicine |
| الوصف: | PRECONNECT is a multicenter study demonstrating the efficacy and tolerability of trifluridine/tipiracil in adult patients with histologically confirmed adenocarcinoma of the colon or rectum and pretreated metastatic lesions. The current article describes the characteristics and outcomes of the Brazilian cohort of patients who underwent trifluridine/tipiracil therapy within PRECONNECT. Brazilian patients (n=55) received oral trifluridine/tipiracil 35mg/m2 twice daily on days 1-5 and 8-12 of each 28-day cycle. The primary endpoint was safety including time to ECOG (Eastern Cooperative Oncology Group) PS (performance status) deterioration, and the secondary endpoints included progression-free survival (PFS) and quality of life (QoL). Baseline characteristics showed only 34.5% of patients underwent ≥3 lines of treatment, 29.1% presented ≥3 metastatic sites and 52.7% showed an ECOG PS of 0. The disease control rate (DCR) was 32.0% and 28.6% in patients with one and two metastatic sites, respectively, the median PFS was 3.0 months (95%CI: 2.5-3.4), and the time to ECOG PS deterioration (≥2) was 5.4 months. Drug-related treatment-emergent adverse events (TEAE) were observed at least once in 87.3% of patients, and the most common (≥40% of patients) hematological TEAEs were neutropenia and anemia; there was no febrile neutropenia case. The shorter time to ECOG PS deterioration showed in the Brazilian subset of patients is likely due to late diagnosis setting compared to the global population, despite that trifluridine/tipiracil showed good DCR results, including patients with two metastatic sites. In conclusion, safety and efficacy results provide confidence in routine practice use and are in line with the PRECONNECT study |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2526-8732 |
| Relation: | https://www.brazilianjournalofoncology.com.br/details/225/en-US/brazilian-cohort-results-of-the-preconnect-study--safety-and-efficacy-of-trifluridine-tipiracil-in-metastatic-colorectal-cancer; https://doaj.org/toc/2526-8732 |
| DOI: | 10.5935/2526-8732.20220364 |
| URL الوصول: | https://doaj.org/article/266e0bdccb014ab7ac0d1a70ef574f20 |
| رقم الانضمام: | edsdoj.266e0bdccb014ab7ac0d1a70ef574f20 |
| قاعدة البيانات: | Directory of Open Access Journals |
| تدمد: | 25268732 |
|---|---|
| DOI: | 10.5935/2526-8732.20220364 |